Methotrexate toxicity-an alarming bell!
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20233183Keywords:
MTX, Psoriasis, Mucositis, Cutaneous necrosis, Toxicity, LeucovorinAbstract
Since its introduction in 1951, methotrexate (MTX) has been widely used as the primary anti-psoriatic agent. However, unsupervised dosing by patients or concurrent use of excessive nonsteroidal anti-inflammatory drugs (NSAIDs) can lead to toxicity. Gastrointestinal symptoms are the most commonly observed manifestations, followed by cutaneous toxicity. In this retrospective study conducted at a tertiary care center in Gujarat, data from patients admitted for MTX toxicity between April 2017 and December 2019 were analyzed. A detailed history, including dosage, duration, signs and symptoms, investigations, treatment, and outcomes, was collected and evaluated. The study included 12 hospitalized patients (aged 35-70 years) with MTX toxicity. Among them, 10 patients had psoriasis, 1 had psoriatic arthritis, and 1 had rheumatoid arthritis with discoid lupus erythematosus. Eleven patients had taken daily oral MTX for one week along with painkillers, while one patient had taken an unknown amount without undergoing any investigations. Mucosal ulceration was observed in all cases, and skin necrosis was seen in 2 patients. Hematological investigations revealed myelosuppression in all patients, with altered renal function in 1 patient. Leucovorin (15 mg/ml) was administered to all patients, resulting in improvement for 10 patients, but 2 patients experienced persistent myelosuppression and succumbed to the toxicity. This study emphasizes the importance of pre-treatment investigations, proper monitoring, and strict avoidance of self-administration when administering MTX. Additionally, the co-administration of drugs such as NSAIDs should be judiciously managed. Folinic acid has shown usefulness in cases of MTX toxicity and overdose. In summary, this study underscores the significance of careful administration and monitoring of MTX, along with the avoidance of self-dosing. It highlights the need for judicious use of co-administered medications, and emphasizes the utility of folinic acid in managing MTX toxicity and overdose.
References
Alencar MS, Avelleira JC. Metotrexate. In: Consenso Brasileiro de Psoríase 2012: guias De avaliação e tratamento Sociedade Brasileira de Dermatologia. 2nd ed. Rio de Janeiro: Sociedade Brasileira de Dermatologia. 2012;67-73.
Bhatnagar A, Verma R, Vasudevan B, Saraswat N. Acute methotrexate toxicity presenting as ulcers in plaques of psoriasis vulgaris. Indian Dermatol Online J. 2015;6:232-3.
Fridlington JL, Tripple JW, Reichenberg JS, Hall CS, Diven DG. Acute methotrexate toxicity seen as plaque psoriasis ulceration and necrosis: A diagnostic clue. Dermatol Online J. 2011;17:2.
Bourré-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: A systematic review. J Rheumatol. 2010;37:1416-21.
Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther. 2007;20:216-28.
Carretero G, Puig L, Dehesa L, Carrascosa JM, Ribera M, Sanchez-Regana M et al. Guidelines on the use of methotrexate in psoriasis (in Spanish). Actas Dermosifiliogr. 2010;101:600-613.
Pearce HP, Wilson BB: Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol. 1996;35:835-8.
Lucas J, Ntuen E, Pearce DJ, Fleischer AB Jr, Feldman SR: Methotrexate: understanding the risk in psoriasis patients. J Dermatolog Treat. 2009;20:311-13.
Montaudie H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol. 2011; 25(2):12-8.
Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382-8.
Bookstaver PB, Norris L, Rudisill C, DeWitt T, Aziz S, Fant J. Multiple toxic effects of low dose methotrexate in a patient treated for psoriasis. Am J Health Syst Pharm. 2008;65:2117-21.
Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. QJM. 1999;92:551-63.
Garcia de Villalta MJ, Ruiz-Genao D, Alvarez- Ruiz S, Aragues M, Fraga J, Fernandez- Herrera J et al. Toxicodermiapormetotrexato con Marcadadismaduracion epidermica. Act as Dermosifiliogr. 2004;95:567-70.
Agarwal KK, Nath AK, Thappa DM. Methotrexate toxicity presenting as ulceration of psoriatic plaques: a report of two cases. Indian J Dermatol Venereol Leprol. 2008;74:481-4.
Maronas-Jimenez L, Castellanos-Gonzalez M, Sanz Bueno J, Vanaclocha Sebastian F. Acral erosions and ulcers: an early sign of severeacute methotrexate toxicity. Act as Dermosifiliogr. 2014;105:322-3.
Breneman DL, Storer TJ, Breneman JC, Mutasim DF. Methotrexate-induced cutaneous ulceration in patients with erythron-dermicmycosis fungoides. Ther Clin Risk Manag. 2008;4:1135-41.
Zackheim HS, Kashani-Sabet M, Hwang ST: Low-dose methotrexate to treat erythrodermic cutaneous T cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol. 1996;34:626-31.
Ben-Amitai D, Hodak E, David M: Cutaneous ulceration: an unusual sign of methotrexate toxicity- first report in a patient without psoriasis. Ann Pharmacother. 1998;32:651-3.
Del Pozo J, Martinez W, Garcia-Silva J, Almagro M, Pena-Penabad C, Fonseca E. Cutaneous ulceration as a sign of methotrexate toxicity. Eur J Dermatol. 2001;11:450-52.
Kurian A, Haber R. Methotrexate-induced cutaneous ulcers in a nonpsoriatic patient: case report and review of the literature. J Cutan Med Surg. 2011;15:275-9.
Fridlington JL, Tripple JW, Reichenberg JS, Hall CS, Diven DG. Acute methotrexate toxicity seen as plaque psoriasis ulceration and necrosis: a diagnostic clue. Dermatol Online J. 2011;17:2.
Puig L. Metotrexato y psoriasis. Barcelona, Marge Medica Books. 2012;4-51.
Puig L. Methotrexate: new therapeutic approaches. Actas Dermosifiliogr. 2014;105:583-9.
Hayashi H, Tazoe Y, Tsuboi S, Horino M, Morishita M, Arai T et al. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet. 2013;28:164-8.
Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008;128:1925-9.
